ABPWW Abpro Holdings, Inc.

BEARISH Impact: 8/10 8-K
Horizon immediate Filed Jun 4, 2026 Processed 8d 11h ago SEC 0001213900-26-065372
8-K context-dependent: Items 3.01

Price Chart

Loading chart...

Executive Summary

Abpro Holdings received final notification from the Nasdaq Listing and Hearing Review Council reaffirming the delisting of its securities for failure to meet the minimum equity standard (Listing Rule 5550(b)(1)) by the February 16, 2026 compliance deadline. The company's common stock and warrants were already trading on the OTC Pink Ltd. tier as of February 23, 2026, and Nasdaq is expected to file a Form 25 to complete the delisting and deregistration under Section 12(b).

Actionable Insight

The delisting is effectively a fait accompli — securities are already on OTC Pink. Expect minimal incremental price impact from this Form 25 filing, but monitor for potential deregistration under Section 12(b), which would eliminate public reporting obligations and further reduce information flow. No path to regain compliance is disclosed.

Key Facts

  • Nasdaq Listing and Hearing Review Council reaffirmed delisting decision on May 28, 2026.
  • Company failed to demonstrate compliance with minimum equity standard (Rule 5550(b)(1)) by February 16, 2026 deadline.
  • Common stock (ABP) and warrants (ABPWW) already trading on OTC Pink Ltd. tier since February 23, 2026.
  • Nasdaq expected to file Form 25 to delist and deregister securities under Section 12(b) in the coming days.
  • No assurances that any broker-dealer will make a market in the common stock or public warrants on OTC Pink.

Financial Impact

Delisting from Nasdaq to OTC Pink severely reduces institutional ownership, liquidity, and transparency. No specific dollar amounts provided.

liquidityinstitutional ownershipmarket access

Risk Factors

  • Potential deregistration under Section 12(b) would eliminate SEC reporting obligations, reducing transparency.
  • No broker-dealer market-making assurances on OTC Pink — liquidity may be extremely limited.
  • OTC Pink trading subject to limited information availability, reduced transparency, and greater volatility.

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)

Documents Analyzed

This report is based on 4 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0001213900-26-065372
Document: 0001213900-26-065372-index-headers.html0001213900-26-065372
Document: 0001213900-26-065372-index.html0001213900-26-065372
Document: 0001213900-26-065372.txt0001213900-26-065372

US Market Status

Market Closed — Opens Mon (53h 9m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access